The latest Canadian research: Cannabinoids can treat COVID-19 and Long COVID , and nebulization is more effective.

A recent review by a Canadian research team suggests that cannabinoids could play a role in preventing and treating both COVID-19 and Long COVID.

In a comprehensive assessment, Canadian scientists presented intriguing insights into the potential role of cannabinoids in combating SARS-CoV-2. The study, titled "Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19", was authored by Cassidy Scott, Stefan Hall, Juan Zhou, and Christian Lehmann, among others, and published in the Journal of Clinical Medicine.

By analyzing extensive existing research, the report explores how compounds from the cannabis plant may play a key role in preventing COVID-19 onset and mitigating its long-term effects. The findings suggest that cannabinoids, particularly those derived from cannabis, may:

• Inhibit viral entry into cells
• Reduce harmful oxidative stress
• Suppress deadly immune overreactions (cytokine storms) in severe cases

The study also highlights cannabinoids' potential in addressing persistent Long COVID symptoms.

Key Findings

1. Blocking Viral Entry

• Certain cannabis extracts may downregulate ACE2 receptors, a primary pathway for SARS-CoV-2 entry into human cells.

2. Reducing Oxidative Stress

• Cannabinoids like CBD can neutralize free radicals, potentially alleviating oxidative damage seen in severe COVID-19.

3. Modulating Immune Response

• Cannabinoids may help control cytokine storms, a dangerous inflammatory reaction in critical COVID-19 cases.

4. Managing Long COVID Symptoms

• The endocannabinoid system (ECS) interacts with neurological functions, making cannabinoids a potential treatment for depression, anxiety, PTSD, insomnia, chronic pain, and appetite loss in Long COVID patients.

Optimal Consumption Methods

• Vaporization is preferable to smoking because it heats cannabis below combustion, reducing respiratory irritation.
• Smoking may worsen lung conditions, counteracting potential benefits.

Need for Further Research

While the preliminary results are promising, the authors caution that the evidence is not yet conclusive, as most studies analyzed were not specifically designed for COVID-19. They call for:

• More targeted clinical trials
• Deeper investigation into the ECS’s pharmacological potential

Conclusion

Cannabinoids show promise in treating acute COVID-19 and Long COVID, but more rigorous studies are needed before they can be recommended as standard therapy. Patients should consult medical professionals before use, especially due to legal and safety considerations.